Literature DB >> 22430958

The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Meredith G Jernigan1, Ellen G Press, M Hong Nguyen, Cornelius J Clancy, Ryan K Shields.   

Abstract

We tested two-drug combinations of doripenem, colistin, gentamicin, and doxycycline against 12 carbapenemase-producing Klebsiella pneumoniae (KPC) isolates by time-kill. The combination of doripenem and colistin reduced the starting inocula by 2 logs for each isolate (range, 2.02 to 6.01 log(10)) and was bactericidal and synergistic against 75 and 50%, respectively. Among colistin- and pan-drug-resistant isolates, synergy was identified in 60 and 67%, respectively. All other combinations were inferior. We are currently evaluating the combination of doripenem and colistin as a frontline therapy for KPC infection.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22430958      PMCID： PMC3370798          DOI： 10.1128/AAC.06364-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.

Authors:  Z A Qureshi; D L Paterson; A Y Peleg; J M Adams-Haduch; K A Shutt; D L Pakstis; E Sordillo; B Polsky; G Sandkovsky; M K Bhussar; Y Doi
Journal:  Clin Microbiol Infect       Date:  2011-09-26       Impact factor: 8.067

2.  In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Authors:  Maria Souli; Irene Galani; Stefanos Boukovalas; Michael George Gourgoulis; Zoi Chryssouli; Kyriaki Kanellakopoulou; Theofano Panagea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

3.  Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

Authors:  May Nguyen; Gregory A Eschenauer; Monique Bryan; Kelly O'Neil; E Yoko Furuya; Phyllis Della-Latta; Christine J Kubin
Journal:  Diagn Microbiol Infect Dis       Date:  2010-03-31       Impact factor: 2.803

4.  Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study.

Authors:  Olympia Zarkotou; Spyros Pournaras; Evangelia Voulgari; Georgios Chrysos; Athanassios Prekates; Dionysios Voutsinas; Katerina Themeli-Digalaki; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2010-04-07       Impact factor: 5.948

5.  Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center.

Authors:  Dror Marchaim; Teena Chopra; Federico Perez; Kayoko Hayakawa; Paul R Lephart; Suchitha Bheemreddy; Christopher Blunden; Andrea M Hujer; Susan Rudin; Maryann Shango; Michelle Campbell; Jastin Varkey; Jessica Slim; Farah Ahmad; Diixa Patel; Ting-Yi Chen; Jason M Pogue; Hossein Salimnia; Sorabh Dhar; Robert A Bonomo; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09       Impact factor: 3.254

Review 6.  Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.

Authors:  Elizabeth B Hirsch; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2010-04-08       Impact factor: 5.790

7.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

8.  Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Authors:  Mitchell J Schwaber; Shiri Klarfeld-Lidji; Shiri Navon-Venezia; David Schwartz; Azita Leavitt; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

Review 9.  Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature.

Authors:  Azza Elemam; Joseph Rahimian; William Mandell
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae.

Authors:  Jennifer Le; Barbara McKee; Warunee Srisupha-Olarn; David S Burgess
Journal:  J Clin Med Res       Date:  2011-05-19
View more
  38 in total

1.  Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.

Authors:  Cornelius J Clancy; Binghua Hao; Ryan K Shields; Liang Chen; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Authors:  Kristina L Bailey; Andre C Kalil
Journal:  Curr Infect Dis Rep       Date:  2015-08       Impact factor: 3.725

3.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.

Authors:  Rebekah Henry; Bethany Crane; David Powell; Deanna Deveson Lucas; Zhifeng Li; Jesús Aranda; Paul Harrison; Roger L Nation; Ben Adler; Marina Harper; John D Boyce; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-01-14       Impact factor: 5.790

Review 5.  Infections in the immunosuppressed host.

Authors:  M Patricia George; Henry Masur; Karen A Norris; Scott M Palmer; Cornelius J Clancy; John F McDyer
Journal:  Ann Am Thorac Soc       Date:  2014-08

Review 6.  Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.

Authors:  Stephanie M Pouch; Michael J Satlin
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

7.  Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Authors:  Reem Almaghrabi; Cornelius J Clancy; Yohei Doi; Binghua Hao; Liang Chen; Ryan K Shields; Ellen G Press; Nicole M Iovine; Bethany M Townsend; Marilyn M Wagener; Barry Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

8.  Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.

Authors:  Thea Brennan-Krohn; Katherine A Truelson; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2017-10-01       Impact factor: 5.790

9.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.